Literature DB >> 33852874

A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.

Harini Ramalingam1, Sonu Kashyap2, Patricia Cobo-Stark1, Andrea Flaten1, Chun-Mien Chang1, Sachin Hajarnis1, Kyaw Zaw Hein2, Jorgo Lika2, Gina M Warner2, Jair M Espindola-Netto2, Ashwani Kumar3, Mohammed Kanchwala3, Chao Xing4, Eduardo N Chini5, Vishal Patel6.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disorder marked by numerous progressively enlarging kidney cysts. Mettl3, a methyltransferase that catalyzes the abundant N6-methyladenosine (m6A) RNA modification, is implicated in development, but its role in most diseases is unknown. Here, we show that Mettl3 and m6A levels are increased in mouse and human ADPKD samples and that kidney-specific transgenic Mettl3 expression produces tubular cysts. Conversely, Mettl3 deletion in three orthologous ADPKD mouse models slows cyst growth. Interestingly, methionine and S-adenosylmethionine (SAM) levels are also elevated in ADPKD models. Moreover, methionine and SAM induce Mettl3 expression and aggravate ex vivo cyst growth, whereas dietary methionine restriction attenuates mouse ADPKD. Finally, Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced c-Myc and Avpr2 mRNA m6A modification and translation. Thus, Mettl3 promotes ADPKD and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AVPR2; METTL3; N(6)-methyladenosine; S-adenosylmethionine; c-Myc; m6A mRNA methylation; mRNA translation; methionine; polycystic kidney disease

Mesh:

Substances:

Year:  2021        PMID: 33852874      PMCID: PMC8172529          DOI: 10.1016/j.cmet.2021.03.024

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   31.373


  71 in total

Review 1.  Chemical Modifications in the Life of an mRNA Transcript.

Authors:  Sigrid Nachtergaele; Chuan He
Journal:  Annu Rev Genet       Date:  2018-09-19       Impact factor: 16.830

2.  Chemical inhibitors make their RNA epigenetic mark.

Authors:  Megan Cully
Journal:  Nat Rev Drug Discov       Date:  2019-11       Impact factor: 84.694

3.  N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells.

Authors:  Yang Wang; Yue Li; Julia I Toth; Matthew D Petroski; Zhaolei Zhang; Jing Crystal Zhao
Journal:  Nat Cell Biol       Date:  2014-01-07       Impact factor: 28.824

4.  Exploring RNA transcription and turnover in vivo by using click chemistry.

Authors:  Cindy Y Jao; Adrian Salic
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-07       Impact factor: 11.205

Review 5.  The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.

Authors:  Almira Kurbegovic; Marie Trudel
Journal:  Cell Signal       Date:  2020-03-04       Impact factor: 4.315

6.  Food Restriction Ameliorates the Development of Polycystic Kidney Disease.

Authors:  Gina Warner; Kyaw Zaw Hein; Veronica Nin; Marika Edwards; Claudia C S Chini; Katharina Hopp; Peter C Harris; Vicente E Torres; Eduardo N Chini
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

7.  Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease.

Authors:  Qian Wang; Patricia Cobo-Stark; Vishal Patel; Stefan Somlo; Pyung-Lim Han; Peter Igarashi
Journal:  Kidney Int       Date:  2017-10-14       Impact factor: 10.612

8.  mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.

Authors:  Junho Choe; Shuibin Lin; Wencai Zhang; Qi Liu; Longfei Wang; Julia Ramirez-Moya; Peng Du; Wantae Kim; Shaojun Tang; Piotr Sliz; Pilar Santisteban; Rani E George; William G Richards; Kwok-Kin Wong; Nicolas Locker; Frank J Slack; Richard I Gregory
Journal:  Nature       Date:  2018-09-19       Impact factor: 49.962

9.  METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.

Authors:  Ting Li; Pei-Shan Hu; Zhixiang Zuo; Jin-Fei Lin; Xingyang Li; Qi-Nian Wu; Zhan-Hong Chen; Zhao-Lei Zeng; Feng Wang; Jian Zheng; Demeng Chen; Bo Li; Tie-Bang Kang; Dan Xie; Dongxin Lin; Huai-Qiang Ju; Rui-Hua Xu
Journal:  Mol Cancer       Date:  2019-06-24       Impact factor: 27.401

10.  A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease.

Authors:  Jing Cai; Xuewen Song; Wei Wang; Terry Watnick; York Pei; Feng Qian; Duojia Pan
Journal:  Genes Dev       Date:  2018-06-11       Impact factor: 11.361

View more
  16 in total

1.  Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.

Authors:  Katharina Hopp; Emily K Kleczko; Berenice Y Gitomer; Michel Chonchol; Jost Klawitter; Uwe Christians; Jelena Klawitter
Journal:  Am J Physiol Renal Physiol       Date:  2022-01-17

2.  Nuclear Condensation of CDYL Links Histone Crotonylation and Cystogenesis in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lin Dang; Xinyi Cao; Tianye Zhang; Yongzhan Sun; Shanshan Tian; Tianyu Gong; Hui Xiong; Peipei Cao; Yuhao Li; Shengqiang Yu; Li Yang; Lirong Zhang; Tong Liu; Kai Zhang; Jing Liang; Yupeng Chen
Journal:  J Am Soc Nephrol       Date:  2022-08-02       Impact factor: 14.978

3.  Decorating Histones in Polycystic Kidney Disease.

Authors:  Harini Ramalingam; Vishal Patel
Journal:  J Am Soc Nephrol       Date:  2022-08-02       Impact factor: 14.978

Review 4.  Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jing Xu; Cheng Xue; Xiaodong Wang; Lei Zhang; Changlin Mei; Zhiguo Mao
Journal:  Front Med (Lausanne)       Date:  2022-07-05

Review 5.  Is autosomal dominant polycystic kidney disease an early sweet disease?

Authors:  Angélique Dachy; Jean-Paul Decuypere; Rudi Vennekens; François Jouret; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2022-01-05       Impact factor: 3.651

6.  Alteration of N6-methyladenosine epitranscriptome profile in lipopolysaccharide-induced mouse mesangial cells.

Authors:  Tao Liu; Xing Xing Zhuang; Xiu Juan Qin; Liang Bing Wei; Jia Rong Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-04       Impact factor: 3.000

7.  Alkbh1-mediated DNA N6-methyladenine modification regulates bone marrow mesenchymal stem cell fate during skeletal aging.

Authors:  Guang-Ping Cai; Ya-Lin Liu; Li-Ping Luo; Ye Xiao; Tie-Jian Jiang; Jian Yuan; Min Wang
Journal:  Cell Prolif       Date:  2022-01-11       Impact factor: 6.831

8.  N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.

Authors:  You-Qing Miao; Wei Chen; Jianfeng Zhou; Qiyang Shen; Ying Sun; Tao Li; Sheng-Chan Wang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

9.  METTL14 promotes prostate tumorigenesis by inhibiting THBS1 via an m6A-YTHDF2-dependent mechanism.

Authors:  Yongjie Wang; Junfei Chen; Wei-Qiang Gao; Ru Yang
Journal:  Cell Death Discov       Date:  2022-03-30

Review 10.  N6-methyladenosine methyltransferases: functions, regulation, and clinical potential.

Authors:  Wei Huang; Tian-Qi Chen; Ke Fang; Zhan-Cheng Zeng; Hua Ye; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2021-07-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.